Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72


Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.

Siraj AK, Bu R, Iqbal K, Parvathareddy SK, Siraj N, Siraj S, Diaz MRF, Rala DR, Benito AD, Sabido MA, Al-Rasheed M, Al-Obaisi KAS, Al-Haqawi W, Victoria IG, Al Balawy W, Abedalthagafi M, Wakil SM, Ajarim D, Mohammed S, Alhussain T, Tulbah A, Al-Badawi IA, Al-Dayel F, Al-Kuraya KS.

Genomics. 2019 Oct 30. pii: S0888-7543(19)30404-5. doi: 10.1016/j.ygeno.2019.09.017. [Epub ahead of print]


Behavior and Outcomes of Pregnancy Associated Breast Cancer

Suleman K, Osmani AH, Al Hashem H, Al Twegieri T, Ajarim D, Jastaniyah N, Al Khayal W, Al Malik O, Al Sayed A.

Asian Pac J Cancer Prev. 2019 Jan 25;20(1):135-138.


Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.

Siraj AK, Pratheeshkumar P, Parvathareddy SK, Divya SP, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Oncotarget. 2018 Dec 18;9(99):37319-37332. doi: 10.18632/oncotarget.26470. eCollection 2018 Dec 18.


FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer.

Siraj AK, Pratheeshkumar P, Parvathareddy SK, Qadri Z, Thangavel S, Ahmed S, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Oncotarget. 2018 Apr 3;9(25):17466-17482. doi: 10.18632/oncotarget.24739. eCollection 2018 Apr 3.


Expanding the spectrum of germline variants in cancer.

Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Al-Badawi IA, Al-Sanea N, Ashari LH, Abduljabbar A, Alhomoud S, Al-Sobhi SS, Tulbah A, Ajarim D, Alzoman K, Aljuboury M, Yousef HB, Al-Dawish M, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.

Hum Genet. 2017 Nov;136(11-12):1431-1444. doi: 10.1007/s00439-017-1845-0. Epub 2017 Oct 3.


XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.

Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, Qadri Z, Ajarim D, Al-Dayel F, Beg S, Al-Kuraya KS.

BMC Cancer. 2017 Sep 11;17(1):640. doi: 10.1186/s12885-017-3627-4.


Reply to "letter to the editor concerning the article-Impact of surgery on survival in stage IV breast cancer".

Al Johani B, Al Malik O, Anwar E, Tulbah A, Alshabanah M, AlSyaed A, Ajarim D, Al-Tweigeri T.

Breast J. 2017 Nov;23(6):775. doi: 10.1111/tbj.12826. Epub 2017 May 8. No abstract available.


Reply to "Letter to the Editor Concerning the Article-Impact of Surgery on Survival in Stage IV Breast Cancer".

Al Johani B, Al Malik O, Anwar E, Tulbah A, Alshabanah M, AlSayed A, Ajarim D, Al-Tweigeri T.

Breast J. 2017 Jan;23(1):119. doi: 10.1111/tbj.12701. Epub 2016 Oct 31. No abstract available.


Impact of Surgery on Survival in Stage IV Breast Cancer.

AlJohani B, AlMalik O, Anwar E, Tulbah A, Alshabanah M, AlSyaed A, Ajarim D, ALTweigeri T.

Breast J. 2016 Nov;22(6):678-682. doi: 10.1111/tbj.12662. Epub 2016 Aug 26.


Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.

Bu R, Siraj AK, Al-Obaisi KA, Beg S, Al Hazmi M, Ajarim D, Tulbah A, Al-Dayel F, Al-Kuraya KS.

Int J Cancer. 2016 Sep 1;139(5):1091-7. doi: 10.1002/ijc.30143. Epub 2016 May 3.


A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.

A L-Tweigeri T, AlSayed A, Alawadi S, Ibrahim M, Ashour W, Jaafar H, Abulkhair O, A L-Abdulkarim H, Khalid H, Ajarim D; Gulf Oncology Research Group (GORG-001).

Cancer Chemother Pharmacol. 2016 Jan;77(1):147-53. doi: 10.1007/s00280-015-2906-5. Epub 2015 Nov 12.


ALK alteration is a frequent event in aggressive breast cancers.

Siraj AK, Beg S, Jehan Z, Prabhakaran S, Ahmed M, R Hussain A, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Breast Cancer Res. 2015 Sep 17;17:127. doi: 10.1186/s13058-015-0610-3.


Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.

Beg S, Siraj AK, Prabhakaran S, Jehan Z, Ajarim D, Al-Dayel F, Tulbah A, Al-Kuraya KS.

Breast Cancer Res Treat. 2015 Jun;151(3):541-53. doi: 10.1007/s10549-015-3430-3. Epub 2015 May 16.


Obesity is a significant risk factor for breast cancer in Arab women.

Elkum N, Al-Tweigeri T, Ajarim D, Al-Zahrani A, Amer SM, Aboussekhra A.

BMC Cancer. 2014 Oct 29;14:788. doi: 10.1186/1471-2407-14-788.


Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway.

Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D, Al-Alwan M.

Br J Cancer. 2014 Oct 14;111(8):1552-61. doi: 10.1038/bjc.2014.453. Epub 2014 Aug 12.


Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.

Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, Inan MS, Kaya N, Park BH, Bin Amer SM.

PLoS One. 2013 May 21;8(5):e63204. doi: 10.1371/journal.pone.0063204. Print 2013.


Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.

Bu R, Bavi P, Abubaker J, Jehan Z, Al-Haqawi W, Ajarim D, Al-Dayel F, Uddin S, Al-Kuraya KS.

Leuk Lymphoma. 2012 Oct;53(10):1971-7. doi: 10.3109/10428194.2012.668286. Epub 2012 Apr 18.


Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules.

Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C.

PLoS One. 2011;6(11):e27339. doi: 10.1371/journal.pone.0027339. Epub 2011 Nov 4.


The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).

Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Hussain AR, Al-Kuraya KS.

J Pathol. 2011 Jul;224(3):355-66. doi: 10.1002/path.2864. Epub 2011 Apr 19.


Survey of utilization of multidisciplinary management tumor boards in Arab countries.

El Saghir NS, El-Asmar N, Hajj C, Eid T, Khatib S, Bounedjar A, Ajarim D, Shamseddine A, Geara F, Jazieh A, Azim HA, Abdelkader Y, Kattan J, Abulkhair O.

Breast. 2011 Apr;20 Suppl 2:S70-4. doi: 10.1016/j.breast.2011.01.011. Epub 2011 Feb 12.


Clinico-pathological pattern of extranodal non-Hodgkin's lymphoma in Saudi Arabia.

Al Diab AR, Aleem A, Qayum A, Al Askar AS, Ajarim DS.

Asian Pac J Cancer Prev. 2011;12(12):3277-82.


Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling.

Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS.

J Pathol. 2010 Oct;222(2):180-90. doi: 10.1002/path.2747.


Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution.

El Weshi A, Allam A, Ajarim D, Al Dayel F, Pant R, Bazarbashi S, Memon M.

Clin Oncol (R Coll Radiol). 2010 Jun;22(5):374-81. doi: 10.1016/j.clon.2010.02.010.


Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, Bavi P, Al-kuraya KS.

Leuk Lymphoma. 2010 Jul;51(7):1305-14. doi: 10.3109/10428191003802365.


Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma.

Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS.

Mol Cancer Ther. 2010 May;9(5):1244-55. doi: 10.1158/1535-7163.MCT-09-1061. Epub 2010 Apr 27.


Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.

Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, Al-Malik OA, Fatani DM, El-Husseiny GA, Elkum NB, Ezzat AA.

Med Oncol. 2010 Sep;27(3):571-7. doi: 10.1007/s12032-009-9251-7. Epub 2009 Jun 13.


Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.

Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GE, Al-Sayed A, Alzahrani H, Alsharif F, Mohareb F, Ajarim D, Tabakhi A, Al-Hussein K.

Exp Hematol. 2009 Jul;37(7):838-48. doi: 10.1016/j.exphem.2009.04.003. Epub 2009 May 14.


S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.

Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P, Al-Kuraya KS.

J Pathol. 2008 Dec;216(4):483-94. doi: 10.1002/path.2433.


Successful outcome of Langerhans cell histiocytosis complicated by therapy-related myelodysplasia and acute myeloid leukemia: a case report.

Al-Anazi KA, Alshehri A, Al-Zahrani HA, Al-Mohareb FI, Maghfoor I, Ajarim D.

Cases J. 2008 Aug 18;1(1):101. doi: 10.1186/1757-1626-1-101.


Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.

Bazarbashi S, Abdelsalam M, Amin T, El-Bassiouni M, Soudy H, Elweshi A, Alhusseiny H, Rehman K, Memon M, Ajarim D.

Chemotherapy. 2008;54(4):315-22. doi: 10.1159/000151353. Epub 2008 Aug 14.


A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer.

Bazarbashi S, El-Bassiouni M, Abdelsalam M, Soudy H, Sanea NA, Jabbar AA, Manji M, Fagih M, Ajarim D.

J Surg Oncol. 2008 Sep 1;98(3):167-74. doi: 10.1002/jso.21097.


Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes.

Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A.

Cancer Res. 2008 Apr 15;68(8):2717-25. doi: 10.1158/0008-5472.CAN-08-0192.


Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience.

Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A, Tulbah A, Al Malik O, Alshabanah M, Ezzat A, Al-Tweigeri T.

BMC Cancer. 2007 Dec 5;7:222.


T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.

El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I.

Leuk Lymphoma. 2007 Sep;48(9):1764-73. Review.


Adult acute myeloblastic leukemia: Experience at King Khalid University Hospital.

Harakati MS, Al-Momen AM, Ajarim DS, Al-Moharib FI, Al-Theyab A, Fawzy EM, Al-Gwaiz L, Al-Khairy KS.

Ann Saudi Med. 1998 May-Jun;18(3):221-5.


The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S.

Neoplasia. 2006 Mar;8(3):190-8.


Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.

Ibrahim EM, Ezzat AA, Rahal MM, Raja MM, Ajarim DS.

Med Oncol. 2005;22(4):343-52.


Loss to follow-up of patients with malignant lymphoma.

Brown S, Belgaumi A, Ajarim D, Kofide A, Al-Saad R, Sabbah R, Ezzat A, Shoukri M, Barr R, Levin A.

Eur J Cancer Care (Engl). 2004 May;13(2):180-4.


Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.

Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Tulbah AM, Al-Malik OA, Al-Shabanah M, Sorbris R.

Br J Cancer. 2004 Mar 8;90(5):968-74.


Appraisal of communication skills and patients' satisfaction in cross-language encounters in oncology practice.

Ibrahim EM, Al-Saad R, Wishi AL, Khafaga YM, El Hussainy G, Nabhan A, Ezzat AA, Ajarim DS, Bazarbashi S, Radwi A, Al-Amro A.

J Cancer Educ. 2002 Winter;17(4):216-21.


Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy.

Baslaim MM, Al Malik OA, Al-Sobhi SS, Ibrahim E, Ezzat A, Ajarim D, Tulbah A, Chaudhary MA, Sorbris RA.

Am J Surg. 2002 Oct;184(4):299-301.


A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.

Bazarbashi S, Rahal M, Raja MA, El Weshi A, Pai C, Ezzat A, Ajarim D, Memon M, Al Fadda M.

Chemotherapy. 2002 Sep;48(4):211-6.


HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer.

Tulbah AM, Ibrahim EM, Ezzat AA, Ajarim DS, Rahal MM, El Weshi AN, Sorbris R.

Med Oncol. 2002;19(1):15-23.


Extramedullary myeloid cell tumours localised to the mediastinum: a rare clinicopathological entity with unique karyotypic features.

Nounou R, Al-Zahrani H H, Ajarim DS, Martin J, Iqbal A, Naufal R, Stuart R, Roberts G, Gyger M.

J Clin Pathol. 2002 Mar;55(3):221-5. Review.


Primary gastrointestinal cancers in the Western Region of Saudi Arabia. Is the pattern changing?

Al-Radi AO, Ayyub M, Al-Mashat FM, Barlas SM, Al-Hamdan NA, Ajarim DS, Ghafouri HM, Koriech OM, Alidrissi HY, Alsonossi AA.

Saudi Med J. 2000 Aug;21(8):730-4.


Primary thyroid lymphoma: a retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma.

Belal AA, Allam A, Kandil A, El Husseiny G, Khafaga Y, Al Rajhi N, Ahmed G, Gray A, Ajarim D, Schultz H, Ezzat A.

Am J Clin Oncol. 2001 Jun;24(3):299-305.


Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.

Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E.

Head Neck. 2001 Jul;23(7):547-58.


Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: clinical features, management, and prognosis of 66 patients.

Ibrahim EM, Ezzat AA, El-Weshi AN, Martin JM, Khafaga YM, Al Rabih W, Ajarim DS, Al-Foudeh MO, Zucca E.

Ann Oncol. 2001 Jan;12(1):53-8.


High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.

Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM.

Breast Cancer Res Treat. 2000 Aug;62(3):237-44.


Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.

Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J.

Med Oncol. 2000 Feb;17(1):39-46.


Supplemental Content

Loading ...
Support Center